Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: DE-114 ophthalmic solutionDrug: Placebo ophthalmic solution
- Registration Number
- NCT01363700
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Brief Summary
The purpose of the study is to demonstrate safety and efficacy of DE-114 ophthalmic solution compared to its Placebo and Olopatadine hydrochloride 0.1% ophthalmic solution in patients with allergic conjunctivitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 87
- Provided signed, written informed consent.
- Has a positive result from an allergen-specific IgE antibody test.
- If a subject is a female of childbearing potential, she must utilize reliable contraceptive throughout the study, and must have a negative urine pregnancy test prior to enrollment into this study.
- Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception.
- Presence of any abnormality or significant illness that could be expected to interfere with the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description 1 DE-114 ophthalmic solution - 3 Olopatadine Hydrochloride 0.1% Ophthalmic Solution - 2 Placebo ophthalmic solution -
- Primary Outcome Measures
Name Time Method Mean Ocular Itching Score Compared to Placebo Period1 Visit 5 (3, 5, and 10 minutes post-CAC) A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean ocular itching score was assessed by the subject at 3, 5, and 10 min post challenge and graded on a 5 points scale of 0-4 where 0=no itching and 4=incapacitating itch. Count unit was defined each eye.
The endpoint used the average score of three time points (3, 5, and 10 minutes) after allergen challenge .Mean Hyperemia Score Compared to Placebo Period1 Visit 5 (5, 10, and 20 minutes post-CAC) A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean palpebral and bulbar conjunctiva hyperemia was assessed by the investigator at 5, 10, and 20 min post challenge and graded on a 4 points scale of 0-3 (0=none and 3= extremely severe). Total hyperemia score is defined as the sum of the palpebral and bulbar conjunctiva scores. Count unit was defined each eye.
The endpoint used the average score of three time points (5, 10, and 20 minutes) after allergen challenge .
- Secondary Outcome Measures
Name Time Method Mean Hyperemia Score Compared to Olopatadine Period2 Visit 7 (5, 10, and 20 minutes post-CAC) A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean palpebral and bulbar conjunctiva hyperemia was assessed by the investigator at 5, 10, and 20 min post challenge and graded on a 4 points scale of 0-3 (0=none and 3= extremely severe). Total hyperemia score is defined as the sum of the palpebral and bulbar conjunctiva scores.
The endpoint used the average score of three time points (5, 10, and 20 minutes) after allergen challenge .Mean Ocular Itching Score Compared to Olopatadine Period2 Visit 7 (3, 5, and 10 minutes post-CAC) A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean ocular itching score was assessed by the subject at 3, 5, and 10 min post challenge on a 5 points scale of 0-4 where 0=no itching and 4=incapacitating itch.
The endpoint used the average score of three time points (3, 5, and 10 minutes) after allergen challenge .
Trial Locations
- Locations (1)
Santen study sites
🇯🇵Osaka, Japan